Both in Pharmaceuticals
PUMA BIOTECHNOLOGY vs Neurogene
Over the past year PBYI returned +102.8% and NGNE returned −14.1%; their daily moves had a correlation of 0.01.
PBYI +102.8% NGNE −14.1%Growth of $1, one year, split-adjusted
| Metric | PBYI | NGNE |
|---|---|---|
| Price | $10.22 | $26.67 |
| Market cap | $527.6M | $533.7M |
| Today | +0.39% | +0.23% |
| 1 month | +5.7% | +0.8% |
| 6 months | +39.0% | −7.8% |
| Year to date | +71.8% | +29.5% |
| 1 year | +100.4% | −22.2% |
| Revenue growth (YoY) | +7.8% | — |
| Gross margin | 77.9% | — |
| Net margin | 14.5% | — |
| P/E (TTM) | 19.7× | — |
| Price / sales | 2.3× | — |
| Net cash | $93.9M | $225.4M |
| Dividend yield | — | — |
| Volatility (60d) | 39.5% | 76.3% |
| Short % of float | 11.6% | 39.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).